168 related articles for article (PubMed ID: 29476017)
21. Hypoxia imaging with
Melsens E; De Vlieghere E; Descamps B; Vanhove C; Kersemans K; De Vos F; Goethals I; Brans B; De Wever O; Ceelen W; Pattyn P
Radiat Oncol; 2018 Mar; 13(1):39. PubMed ID: 29514673
[TBL] [Abstract][Full Text] [Related]
22. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
Hong CR; Wilson WR; Hicks KO
Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
[TBL] [Abstract][Full Text] [Related]
23. Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
Hunter FW; Young RJ; Shalev Z; Vellanki RN; Wang J; Gu Y; Joshi N; Sreebhavan S; Weinreb I; Goldstein DP; Moffat J; Ketela T; Brown KR; Koritzinsky M; Solomon B; Rischin D; Wilson WR; Wouters BG
Cancer Res; 2015 Oct; 75(19):4211-23. PubMed ID: 26297733
[TBL] [Abstract][Full Text] [Related]
24. A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells.
Maekawa H; Miyoshi H; Yamaura T; Itatani Y; Kawada K; Sakai Y; Taketo MM
Mol Cancer Ther; 2018 Oct; 17(10):2187-2196. PubMed ID: 29970483
[TBL] [Abstract][Full Text] [Related]
25. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
Saggar JK; Tannock IF
Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
[TBL] [Abstract][Full Text] [Related]
26. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.
Peeters SG; Zegers CM; Biemans R; Lieuwes NG; van Stiphout RG; Yaromina A; Sun JD; Hart CP; Windhorst AD; van Elmpt W; Dubois LJ; Lambin P
Clin Cancer Res; 2015 Jul; 21(13):2984-92. PubMed ID: 25805800
[TBL] [Abstract][Full Text] [Related]
27. Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer.
Kim HG; Kim CW; Lee DH; Lee JS; Oh ET; Park HJ
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491980
[TBL] [Abstract][Full Text] [Related]
28. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
[TBL] [Abstract][Full Text] [Related]
29. [
McNeal KC; Reeves KM; Song PN; Lapi SE; Sorace AG; Larimer BM
Nucl Med Biol; 2024; 134-135():108918. PubMed ID: 38772123
[TBL] [Abstract][Full Text] [Related]
30. Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
Nesbitt H; Byrne NM; Williams SN; Ming L; Worthington J; Errington RJ; Patterson LH; Smith PJ; McKeown SR; McKenna DJ
Clin Cancer Res; 2017 Apr; 23(7):1797-1808. PubMed ID: 27697998
[No Abstract] [Full Text] [Related]
31. Evofosfamide, a new horizon in the treatment of pancreatic cancer.
Pourmorteza M; Rahman ZU; Young M
Anticancer Drugs; 2016 Sep; 27(8):723-5. PubMed ID: 27232101
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
[TBL] [Abstract][Full Text] [Related]
33.
Reeves KM; Song PN; Angermeier A; Della Manna D; Li Y; Wang J; Yang ES; Sorace AG; Larimer BM
Clin Cancer Res; 2022 Jan; 28(2):327-337. PubMed ID: 34615724
[TBL] [Abstract][Full Text] [Related]
34. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
Hegde A; Jayaprakash P; Couillault CA; Piha-Paul S; Karp D; Rodon J; Pant S; Fu S; Dumbrava EE; Yap TA; Subbiah V; Bhosale P; Coarfa C; Higgins JP; Williams ET; Wilson TF; Lim J; Meric-Bernstam F; Sumner E; Zain H; Nguyen D; Nguyen LM; Rajapakshe K; Curran MA; Hong DS
Clin Cancer Res; 2021 Jun; 27(11):3050-3060. PubMed ID: 33771853
[TBL] [Abstract][Full Text] [Related]
35. Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.
Hunter FW; Devaux JBL; Meng F; Hong CR; Khan A; Tsai P; Ketela TW; Sharma I; Kakadia PM; Marastoni S; Shalev Z; Hickey AJR; Print CG; Bohlander SK; Hart CP; Wouters BG; Wilson WR
Mol Pharmacol; 2019 Jun; 95(6):638-651. PubMed ID: 30979813
[TBL] [Abstract][Full Text] [Related]
36. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
[TBL] [Abstract][Full Text] [Related]
37. Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure.
Francipane MG; Bulanin D; Lagasse E
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013771
[TBL] [Abstract][Full Text] [Related]
38. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
39. Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.
Malkomes P; Lunger I; Luetticke A; Oppermann E; Haetscher N; Serve H; Holzer K; Bechstein WO; Rieger MA
Ann Surg Oncol; 2016 Sep; 23(9):2849-57. PubMed ID: 27059026
[TBL] [Abstract][Full Text] [Related]
40. Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer.
Lima EABF; Song PN; Reeves K; Larimer B; Sorace AG; Yankeelov TE
Math Biosci Eng; 2023 Sep; 20(10):17625-17645. PubMed ID: 38052529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
